BiomX Inc. COmmon Stock (PHGE)

Competitors to BiomX Inc. COmmon Stock (PHGE)

Axovant Gene Therapies Ltd.

Although Axovant primarily focuses on gene therapies, they have shown interest in microbiome research as a potential avenue for treatment. The competition arises from the emerging understanding of the microbiome's role in gene therapy outcomes, which may influence BiomX's market and research efforts. Yet, Axovant’s established presence in gene therapy with existing relationships and funding can give them a broad competitive advantage in other related areas.

Evelo Biosciences, Inc.

Evelo Biosciences is developing therapies based on specific strains of bacteria intended to influence systemic health. Their unique approach and focus on innate immunity may represent a competitive differentiation in the microbiome sector. While BiomX is focused on targeted bacteriophage therapies, Evelo’s advanced clinical stage candidates might provide it with a first-mover advantage over BiomX in certain therapeutic areas, thus positioning them as a strong competitor.

Rebiotix, a Ferring Company

Rebiotix specializes in restoring healthy microbiota through its microbiota-based therapies, focusing similarly on conditions influenced by microbiome health. Their existing products and a strong position in the fecal microbiota transplantation space give them a competitive edge in terms of product maturity. BiomX, while leveraging innovative approaches, currently lacks the commercialization that Rebiotix has achieved, making Rebiotix a significant competitor in the space.

Seres Therapeutics, Inc. 

Seres Therapeutics is another company developing microbiome-based therapeutics. They have advanced their lead product candidate into late-stage clinical trials, positioning themselves well within the competitive landscape. Seres’s extensive clinical data and proven ability to attract significant funding may present an advantage over BiomX, particularly in terms of their credibility within the market and relationships with regulatory bodies.

Synthetic Biologics, Inc.

Synthetic Biologics focuses on developing therapies for the microbiome, particularly in areas related to gastrointestinal health, which overlaps with BiomX's aim to leverage the microbiome for therapeutic solutions. Both companies are directed towards treating diseases through modulation of the microbiome, but Synthetic Biologics has established collaborations and a broader pipeline that may give it an edge in drug development timelines and partnerships.